Comparative Pharmacology
Head-to-head clinical analysis: HALCION versus OXAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALCION versus OXAZEPAM.
HALCION vs OXAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Cyclosporine
Terminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Oxazepam."